Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 - Cahn, A; Raz, I; Leiter, LA (Diabetes Care, 2021)